
==== Front
J Immunother Cancer
J Immunother Cancer
jitc
jitc
Journal for Immunotherapy of Cancer
2051-1426
BMJ Publishing Group BMA House, Tavistock Square, London, WC1H 9JR

39237261
10.1136/jitc-2024-009376
jitc-2024-009376
Commentary
2520
1506
scRNA+ TCR-seq revealed dual TCR T cells antitumor response in the TME of NSCLC
Peng Qi 10992976521@qq.com

Xu Yuanyuan 102679345525@qq.com

http://orcid.org/0000-0001-6960-4003
Yao Xinsheng 1immunology@126.com

1 Department of Immunology, Zunyi Medical University, Zunyi, China
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Additional supplemental material is published online only. To view, please visit the journal online (https://doi.org/10.1136/jitc-2024-009376 ).

No, there are no competing interests.

Professor; immunology@126.com
QP and YX are joint first authors.

2024
04 9 2024
12 9 e00937619 8 2024
Copyright © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Abstract

The intricate origins, subsets, and characteristics of TCR (T Cell Receptor) s, along with the mechanisms underpinning the antitumor response of tumor-infiltrating T lymphocytes within the tumor microenvironment (TME) remain enigmatic. Recently, the advent of single-cell RNA+TCR-sequencing (scRNA+TCR seq) has revolutionized TME analysis, providing unprecedented insight into the origins, cell subsets, TCR CDR3 compositions, and the expression patterns of response/depletion factors within individual tumor-infiltrating T lymphocytes. Our analysis of the shared scRNA+TCR seq dataset revealed a substantial presence of dual TCR T cells, characterized by clonal hyperplasia and remarkable migratory prowess across various tissues, including blood, normal, peritumoral, and tumor tissues in non-small cell lung cancer patients. Notably, dual TCR CD8+T cells predominantly fell within the CXCL13+subset, displaying potent antitumor activity and a strong preference for tumor tissue residency. Conversely, dual TCR CD4+T cells were predominantly classified as CD5+ or LMNA+subsets, exhibiting a more even distribution across diverse tissue types. By harnessing scRNA+TCR seq and other cutting-edge technologies, we can delve deeper into the effects and mechanisms that regulate the antitumor response or tolerance of dual TCR T cells. This innovative approach holds immense promise in offering fresh perspectives and avenues for advancing research on TIL (Tumor infiltrating lymphocyte)s within the TME.

Tumor infiltrating lymphocyte - TIL
Tumor microenvironment - TME
T cell Receptor - TCR
Lung Cancer
Guizhou Provincial High Level Innovative Talent Fund No.(2018)5637 http://dx.doi.org/10.13039/501100001809 National Natural Science Foundation of China 82160279
==== Body
pmc The composition, characteristics and response effects of tumor-infiltrating T cell subsets in the tumor microenvironment (TME) are key targets for analyzing tumor cell immune escape mechanisms and informing tumor diagnosis, prognosis and immunotherapy. However, the high heterogeneity of tumor-infiltrating T cells has been puzzling immunologists.1 The successful application of single-cell RNA+TCR-sequencing (scRNA+TCR seq) in tumor-infiltrating T cell research can annotate the status of each T cell subset in the TME and their clone expansion, analyze the expression of cytokines, cytokine receptors and transcription factors of each T cell, and analyze the composition and characteristics of the pairing sequence of TCR (T Cell Receptor) CDR3 of each T cell. This enables identification of potential tumor antigen epitopes that may drive TME responses, providing a transformative advance for TIL (Tumor infiltrating lymphocyte) research.25

The adaptive immune response of T cells to antigenic epitopes is based on the clonal selection theory of “one lymphocyte expresses only one type of TCR” which is mainly achieved through the rearrangement of germ line V(D)J allelic exclusion.6 However, dual TCR-expressing lymphocytes caused by incomplete allelic exclusion rearrangement were first reported in 1988,79 and their role in autoimmunity,10 infection11 and transplant12 are supported by extensive experimental evidence. At present, the antitumor effect of dual TCR T cells has been confirmed in a mouse model, where dual TCR T cells inhibited the growth of melanoma cells (B16-ova and B16-gp33).13 Dual TCR CD8+T cells (recognition of tumor-specific Ag and recognition of endogenous Ag in the pancreas) are effective against tumors without serious side effects.14 Dual TCR T cells were increased and showed antitumor effects in B16F10 melanoma-specific tumor-infiltrating T cells.15 Although a large number of experiments have confirmed the existence of a high proportion of dual TCR T cells in human peripheral blood,16 17there is currently a paucity of TIL studies from human clinical tumors assessing whether dual TCR T cells in peripheral blood can enter the TME and exert anti-tumor effects.

He et al recently sequenced scRNA+TCR seq through tumor tissue, tumor adjacent tissue, normal tissue, and peripheral blood samples of 5 non-small cell lung cancer (NSCLC) patients. This innovative discovery confirmed the antitumor effects of two major subsets,CD4+CXCL13+T cells (T) and CD8+CXCL13+T cells (T).18 Based on the scRNA+TCR seq data of 20 samples shared in the original article (cloned proliferation T cells with clone count ≥2), we calculated the number of dual TCR CD4+T and dual TCR CD8+T in each tissue from each patient, their proportion, clonability, overlap, VJ usage, TCR characteristics, and so on. The distribution and differences of dual TCR CD4+T and dual TCR CD8+T in tumor tissue, tumor adjacent tissue, normal tissue, and peripheral blood were compared and statistically analyzed and the proportion differences between 10 CD4+T subsets and 9 CD8+T subsets as defined in the original article were calculated. The composition of TCR CDR3 of dual TCR CD4+T and dual TCR CD8+T was compared with that of antitumor response T cells which was identified in the original study. The summary diagram of this experimental analysis is shown in online supplemental figure 1. For specific sharing data information, analysis steps and methods, see the “Materials and methods” section in online supplemental material 1. The number and proportion of dual TCR T cells analyzed are shown in online supplemental table 1. We compared and analyzed the main composition and characteristics of dual TCR CD4+T and dual TCR CD8+T in 20 samples from 5 NSCLC patients, as shown in figure 1.

Figure 1 Single-cell RNA+TCR-sequencing (scRNA+TCR seq) revealed dual TCR T cells antitumor response in the TME of NSCLC. (A) Dual TCR CD4+T and dual TCR CD8+T ratios in blood, normal, peri, and tumor tissue of each patient. (B) Dual TCR CD4+T CDR3 overlap and dual TCR CD8+T CDR3 overlap in blood, normal, peri, tumor tissue of each patient. (C) TRAV, TRAJ, TRBV, TRBJ usage of single TCR T cells and dual TCR T cells. (D) Dual TCR T cells accounted for the proportion of total dual TCR T cells in blood, normal, peri, and tumor tissue. (E) Ratios of dual TCR CD4+T and dual TCR CD8+T in each subset. (F) Single TCR T and dual TCR T diversity (1/DS). (G) Single TCR T cells and dual TCR T cells clonality (clone count:2–5, 6–9,≥10). (Original clones proliferating to cell numbe r≥2 in online supplemental table 2), including ‘single TCR T cell+dual TCR T cell’ ≥2 clones. For instance, P1_TCR_286 clone type (5 cells) in CD4+T cells in online supplemental table 2)=single TCR CD4+T (1 cell)+dual TCR CD4+T (4 cells), but in our analysis, single TCR and dual TCR were separated for comparative analysis. Therefore, single TCR or dual TCR T with cell number 1 was not analyzed in clonal amplification analysis.) (H) Number, sequence composition, source patient and tissue, and subsets of dual TCR CD4+T and dual TCR CD8+T from the top five high-frequency clones. TCR, T Cell Receptor; TRAV, T cell receptor alpha chain Variable gene; TRAJ, T cell receptor alpha chain Jointing gene; TRBV, T cell receptor beta chain Variable gene; TRBJ, T cell receptor beta chain Jointing gene; NSCLC, non-small cell lung cancer; TME, tumor microenvironment.

(1) A certain proportion (1.04%–14.78%) of dual TCR CD4+T and dual TCR CD8+T (figure 1A) were present in blood, normal, peritumor, and tumor tissues of each patient, except for CD8+T cells in P3. Additionally, CDR3 overlap of dual TCR CD4+T and CDR3 overlap of dual TCR CD8+T occurred between blood, normal, peri, and tumor tissues in each patient (figure 1B). The results showed that both dual TCR CD4+T and dual TCR CD8+T existed in 2–4 types of tissues. It is suggested that dual TCR T cells may migrate from peripheral blood to local normal tissue, adjacent to tumor tissue, and into tumor tissue, They may be involved in specific antitumor responses.

(2) The V and J usage of single TCR T cells and dual TCR T cells was basically the same (figure 1C). However, in the high-frequency usage family of dual TCR T cells, TRBV5-6/6-5/9, TRAV22/23. The usage of TRAJ6/27/37/42 was significantly higher than that of single TCR T cells, suggesting that dual TCR T cells may respond to unique tumor epitopes.

(3) The proportion of dual TCR CD4+T was higher in normal while the proportion of dual TCR CD8+T was significantly increased in tumor (figure 1D), suggesting that dual TCR CD8+T played a stronger tumor killing effect than dual TCR CD4+T.

(4) Dual TCR CD4+T was mainly derived from CD5+T (47.11%) and LMNA+T (28.78%) subsets, suggesting that dual TCR CD4+T may play a major role in immune regulation. Dual TCR CD8+T was mainly derived from CXCL13+T subset (51.61%) (figure 1E), suggesting that dual TCR CD8+T may mainly play a tumor-killing role.

(5) The number of dual TCR T cells with clone count ≥2 was much less than that of single TCR T cells with clone count ≥2. The diversity of dual TCR T cells was significantly lower than that of single TCR T cells (figure 1F). It is suggested that dual TCR T cells are not the dominant effector cell population in response. Dual CD4+T clonality (ratio greater than equal 10) was higher than single TCR T, dual TCR CD8+T clonality (ratio greater than equal 10) was lower than single TCR T(figure 1G), dual TCR T cells had lower diversity and higher percentage of clonal proliferation. These results suggest that, like single TCR T cells, dual TCR T cells may be involved in antitumor response.

(6) The top five dual TCR CD4+T subsets of high-frequency clonal hyperplasia (56, 33, 31,2 9, 27 cloned cells, respectively) were mainly derived from normal and peri tissue sites of patients with P1 but belonged to the CD5+, LMNA+, MKI67+ and CCL4+ subsets (figure 1H). It is suggested they play the role in chemotaxis and immune regulation. The top five high-frequency clones of dual TCR CD8+T subsets (99, 56, 48, 41, 28 cloned cells, respectively) were mainly derived from tumor tissue sites of P5, P1, and P4 patients (few clones in normal and peri). The main class belongs to CXCL13+T subset while a few belong to MKI67, ANXA1, GZMK subsets (figure 1H). It is suggested that they mainly play an immune-killing effect.

(7) In the antitumor T cells of P4 or P5 patients verified in the original paper, five clones of CXCL13+proliferated in the CD4+T (TCR-1 to TCR-5) or CD8+T (TCR-1 to TCR-5) response subsets (original text, online supplemental table 2 and online supplemental table 8). Our in-depth analysis found that effective P5-CD8+CXCL13+T cells (TCR-1, the same CDR3 was found in dual TCR CD8+T(P5_TCR_3, 99 cells) cloned at high frequency (α1: TRAV22/TRAJ27, CAVGHNTNAGKSTF; α2:TRAV23DV6/TRAJ44, CAASNTGTASKLTF; β:TRBV9/TRBJ2-2, CASSVVRGGELFF); Effective P5-CD8+CXCL13+T cells (TCR-3), the same CDR3 was found in dual TCR CD8+T (P5_TCR_10, 11 cells) cloned at high frequency (α1:TRAV12-1/TRAJ42: CAVNFYGGSQGNLIF; α2: TRAV12-3/TRAJ33, CAMSASNYQLIW; β:TRBV3-1/TRBJ2-1, CASSPSPGYYNEQFF); Play to the effect of P4 - CXCL13+CD8 + T cells (TCR-2), the same CDR3 was found in dual TCR CD8+T (P4_TCR_9, 28 cells) cloned at high frequency (α 1: TRAV21/TRAJ49, CAVLYTGNQFY; α2:TRAV24/TRAJ45, CAFYTGGGADGLTF; β:TRBV6-4/TRBJ2-6, CASSPGRPSSGANVLTF); At the same time, the only effective P4-CD4+CXCL13+T cells (TCR-1), the same CDR3 was found in dual TCR CD4+T (P4_TCR_229, 2 cells, 1 CXCL13+T cells, 1 MKI67+T cells) cloned at high frequency (α1:TRAV12-1/TRAJ3, CVVNMDSSASKIIF; α2: TRAV2/TRAJ5, CAVRDMDTGRRALTF; β:TRBV5−4/TRBJ2-1, CASSLPGTGENEQFF). The results indicate that dual TCR CD4+T and dual TCR CD8+T with high-frequency clone proliferation are both involved in the antitumor response effect.

In summary, we report for the first time the existence of dual TCR T cells in the blood, normal, peri, and tumor tissues of each patient, as confirmed by strictly controlling the composition characteristics of T cell subsets in scRNA-seq and scTCR-seq data. These unique dual TCR T cells exhibit the ability to migrate across four tissue types. Dual TCR T cells display high clonal proliferation, especially dual TCR CD8+CXCL13+T in tumor tissue, suggesting a potential antitumor response effect. Five CD8+CXCL13+T cells validated in the original text demonstrate antitumor effects in P4 or P5 patients, respectively. Three of them were found to be highly cloned dual TCR T sources (sharing TCR β CDR3 with single TCR T cells). Two CD4+CXCL13+T cells validated in the original text to exert effect. One of them is a highly cloned dual TCR T source (sharing TCR β CDR3 with single TCR T cells), suggesting dual TCR T cells represent a “new subgroup TIL” for antitumor response.

The detailed mechanism of the allelic exclusion and incomplete allelic exclusion V (D) J rearrangement is unclear, the proportion and self-tolerance selection mechanism of single TCR T or dual TCR T cells rearranged by the germ line V (D) J gene according to two rearrangement mechanisms have not been elucidated.1922 However, under physiological conditions, there is a high proportion of dual receptor lymphocytes in both central and peripheral regions of individuals, as well as evidence of dual receptor T cell effects in autoimmune, antitumor, transplant rejection, and aging.2325

Does the TCR of dual TCR T cells confer an advantage in recognizing novel tumor antigen epitopes? Do dual TCR T cells mount a stronger response than single TCR T cells? Are dual TCR T cells prevalent across different types of TME? These are worthy questions for further research and requiring greater researcher participation. This study, for the first time, identified a new responsive TIL subgroup using scRNA+TCR seq analysis of the TME in NSCLC. Identification and characterization of dual TCR T cells provides a potential novel area of exploration within TIL research.

supplementary material

10.1136/jitc-2024-009376 online supplemental file 1

Acknowledgements

Thanks to Jingjing He et al for providing shared single-cell RNA+TCR sequencing sample data.

Data availability statement

The data analyzed in this experiment are from the attached table of the original text. He et al, Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response. Cell Research, 2022. 32: p. 530–542. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160085/41422_2022_627_MOESM7_ESM.xlsx). The analysis steps and methods of the results in this article can be found in online supplemental material.

Funding: This study was supported by the National Natural Science Foundation of China (82160279) and the Guizhou Provincial High Level Innovative Talent Fund (No.(2018)5637).

Provenance and peer review: Not commissioned; externally peer reviewed.

Patient consent for publication: Not applicable.
==== Refs
References

1 Lei X Lei Y Li J-K et al Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy Cancer Lett 2020 470 126 33 10.1016/j.canlet.2019.11.009 31730903
2 Christodoulou MI Zaravinos A Single-Cell Analysis in Immuno-Oncology Int J Mol Sci 2023 24 8422 10.3390/ijms24098422 37176128
3 Gohil SH Iorgulescu JB Braun DA et al Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy Nat Rev Clin Oncol 2021 18 244 56 10.1038/s41571-020-00449-x 33277626
4 Zhang Y Wang D Peng M et al Single-cell RNA sequencing in cancer research J Exp Clin Cancer Res 2021 40 81 10.1186/s13046-021-01874-1 33648534
5 Zheng L Qin S Si W et al Pan-cancer single-cell landscape of tumor-infiltrating T cells Science 2021 374 abe6474 10.1126/science.abe6474 34914499
6 Burnet FMS The clonal selection theory of acquired immunity 1959 Available https://www.biodiversitylibrary.org/bibliography/8281
7 Malissen M Trucy J Letourneur F et al A T cell clone expresses two T cell receptor alpha genes but uses one alpha beta heterodimer for allorecognition and self MHC-restricted antigen recognition Cell 1988 55 49 59 10.1016/0092-8674(88)90008-6 3262424
8 Triebel F Breathnach R Graziani M et al Evidence for expression of two distinct T cell receptor beta-chain transcripts in a human diphtheria toxoid-specific T cell clone J Immunol 1988 140 300 4 2961810
9 Matis LA Ezquerra A Coligan JE Expression of two distinct T cell receptor alpha/beta heterodimers by an antigen-specific T cell clone J Exp Med 1988 168 2379 84 10.1084/jem.168.6.2379 2848922
10 Schuldt NJ Binstadt BA Dual TCR T Cells: Identity Crisis or Multitaskers? J Immunol 2019 202 637 44 10.4049/jimmunol.1800904 30670579
11 Yang L Jama B Wang H et al TCRα reporter mice reveal contribution of dual TCRα expression to T cell repertoire and function Proc Natl Acad Sci U S A 2020 117 32574 83 10.1073/pnas.2013188117 33288689
12 Balakrishnan A Morris GP The highly alloreactive nature of dual TCR T cells Curr Opin Organ Transplant 2016 21 22 8 10.1097/MOT.0000000000000261 26555233
13 Gladow M Uckert W Blankenstein T Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors Eur J Immunol 2004 34 1882 91 10.1002/eji.200425041 15214036
14 Weinhold M Sommermeyer D Uckert W et al Dual T cell receptor expressing CD8+ T cells with tumor- and self-specificity can inhibit tumor growth without causing severe autoimmunity J Immunol 2007 179 5534 42 10.4049/jimmunol.179.8.5534 17911640
15 Jang HJ Caron C Lee CK et al Dual receptor T cells mediate effective antitumor immune responses via increased recognition of tumor antigens J Immunother Cancer 2023 11 e006472 10.1136/jitc-2022-006472 37188395
16 Padovan E Casorati G Dellabona P et al Expression of two T cell receptor alpha chains: dual receptor T cells Science 1993 262 422 4 10.1126/science.8211163 8211163
17 Gavin MA Rudensky AY Dual TCR T cells: gaining entry into the periphery Nat Immunol 2002 3 109 10 10.1038/ni0202-109 11812982
18 He J Xiong X Yang H et al Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response Cell Res 2022 32 530 42 10.1038/s41422-022-00627-9 35165422
19 Schlissel M Allelic exclusion of immunoglobulin gene rearrangement and expression: why and how? Semin Immunol 2002 14 207 12 10.1016/S1044-5323(02)00044-1 12160648
20 Vettermann C Schlissel MS Allelic exclusion of immunoglobulin genes: models and mechanisms Immunol Rev 2010 237 22 42 10.1111/j.1600-065X.2010.00935.x 20727027
21 Outters P Jaeger S Zaarour N et al Long-Range Control of V(D)J Recombination & Allelic Exclusion: Modeling Views Adv Immunol 2015 128 363 413 10.1016/bs.ai.2015.08.002 26477371
22 Corcoran AE Immunoglobulin locus silencing and allelic exclusion Semin Immunol 2005 17 141 54 10.1016/j.smim.2005.01.002 15737575
23 Zhu L Peng Q Li J et al scRNA-seq revealed the special TCR β & α V(D)J allelic inclusion rearrangement and the high proportion dual (or more) TCR-expressing cells Cell Death Dis 2023 14 487 10.1038/s41419-023-06004-7 37524693
24 Zhu L Peng Q Wu Y et al scBCR-seq revealed a special and novel IG H&L V(D)J allelic inclusion rearrangement and the high proportion dual BCR expressing B cells Cell Mol Life Sci 2023 80 319 10.1007/s00018-023-04973-8 37804328
25 Jun L Lanwei Z Jiayi W et al A new immunological index for the elderly: high proportion of multiple TCR T cells based on scRNA-seq Aging Dis 2023 10.14336/AD.2023.0509-01
